Recent Business Highlights

North America Generics: Growth driven by limited competition products Portfolio Channel • 2018 • . Oral solid dosages account for almost 80% of the current revenues Injectables accounting for 20% of the revenues Retail is the predominant class of trade for the business contributing more than 60% of current revenues Current OTC presence broadly in private Label segment . 2021 More than 50% of revenues to come from Injectables, Topicals and other complex dosage forms Initiate monetization of Biosimilars assets Specialized channels like Oncology Clinics, Hospitals, OTC are expected to form 60% of the mix OTC Brands to become relevant part of business Customer Plant • Exclusive focus on trade partners across retailers, Distributors and GPOs Increased relevance of other stakeholders like Patients, Physicians and Payors · More than 70% revenues reliant on internal manufacturing sites • Diversified manufacturing network with almost 50% of revenues coming from partner manufacturing sites 17

View entire presentation